Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Sotrastaurin||AEB071||PKC Inhibitor (Pan) 11||Sotrastaurin (AEB071) is a pan-PKC inhibitor, which induces cell cycle arrest and apoptosis (PMID: 19491325, PMID: 31261030).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||uveal melanoma||not applicable||Sotrastaurin||Phase I||Actionable||In a Phase I trial, AEB071 treatment was safe and tolerable in patients with uveal melanoma and led to a partial response in 3% (4/153), stable disease in 50% (76/153) with a median duration of 15 weeks, and a median progression-free survival of 3.5 months (PMID: 32029634; NCT01430416).||32029634|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT01430416||Phase I||Sotrastaurin||Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients||Completed||USA||3|
|NCT02285244||Phase II||Sotrastaurin||Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation||Withdrawn||0|